Solta Medical announced Gary Gemignani as its Chief Financial Officer (CFO), effective March 28, 2022.
Solta is a global aesthetic medical device company focused on the development, manufacturing and sale of innovative technologies that provide aesthetic and therapeutic benefits.
Gemignani has more than 35 years of financial and corporate strategy experience, and has served in multiple CFO roles at various life sciences and pharmaceutical companies. Earlier in his career, he served in numerous global finance functions for Novartis Pharmaceuticals, Prudential Financial and Wyeth, which followed a lengthy tenure at Arthur Andersen.
"Gary has a well-established track record in the life sciences industry, and his expertise in both finance and operations makes him a welcome addition to our Solta leadership team," said Scott A. Hirsch, CEO of Solta. "I have known Gary for several years, and I am confident his global financial experience is the right match for us as we embark upon this new chapter for Solta and launch our IPO, subject to market conditions, approvals and other factors."